None listed
Conditions
Interventions
Dietary Supplement : Test product: The test product is a dark brown soft capsule that contains a mixed extract of purslane and perilla seeds.
Control food (placebo): The control or placebo, is a dar
Sponsors
MnF Korea
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: All research subjects participated in the human application test by satisfying the following criteria. 1) Adult men and women between the ages of 20 and 75 at the time of screening 2) A person who voluntarily decides to participate after listening to and fully understanding the detailed explanation of this study and agrees in writing to abide by the precautions.
Exclusion criteria
Exclusion criteria: Research subjects were excluded from participation in the human application test if any of the following criteria were me ; 1) A person whose WBC is less than 3000/µl or greater than 8000/µl in the screening test. 2) Subjects with a BMI of less than 18.5 kg/m2 at the time of screening 3) Those with a history of drug and clinically significant hypersensitivity reactions 4) Those with thyroid or pituitary disease 5) Those with acute severe cardiovascular disease such as renal failure, myocardial infarction, or stroke 6) Those who have or have a history of immune system disease or severe liver or kidney failure 7) Those who have or have a history of systemic diseases such as malignant tumors, lung diseases, leukemia, collagen disease, multiple sclerosis, allergic skin diseases and other autoimmune diseases 8) Those diagnosed with diabetes 9) Those with a history of gastrointestinal diseases (e.g., Crohn's disease) or gastrointestinal surgery (except for simple appendectomy or hernia surgery) that may affect the absorption of the product for human application test 10) A person who has experience of consuming medicines, herbal medicines, or health functional foods that can affect immunity within 2 weeks before the first intake of products for human application (in the case of health functional foods, after a one-week withdrawal period before the first intake) can participate) 11) Those who have received antipsychotic drug treatment within 2 months prior to screening 12) Those who have a history of treatment for alcoholism or drug abuse 13) Those who participated in other human application tests within 2 months before the screening test 14) A person who shows the following results in a laboratory test ? AST or ALT > twice the upper limit of the reference range ? Serum Creatinine > 2.0 mg/dl 15) Pregnant or lactating women 16) If women of childbearing potential do not accept proper contraception (except for women who have undergone sterilization) 17) A person who is judged unsuitable for participation in the study by the director of the study due to other reasons, including diagnostic test results.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Nature Killer Cell activity | — |
Secondary
| Measure | Time frame |
|---|---|
| Cytokine IL-6;Cytokine IL-12;Interferon-gamma; Upper Respiratory Symptom Survey | — |
Countries
Korea, Republic of
Contacts
Public ContactEun-Ock Park
Jeonbuk National University Hospital
Outcome results
None listed